중환자실에서 Tigecycline과 Amikacin의 병합 치료 후 호전된 광범위약제내성 Acinetobacter baumannii 폐렴 1예
Extreme Drug Resistant Acinetobacter Nosocomial Ventilator-Associated Pneumonia Treated Successfully with Tigecycline and Amikacin in Intensive Care Unit
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Infections due to multidrug resistant Acinetobacter baumannii have become a challenging problem in intensive care units. Tigecycline is a derivative of minocyline, and has provided new hope for the treatment of multidrug-resistant A. baumannii infections. Because isolates showing reduced susceptibility to minocycline or tigecycline have emerged in many countries, empirical combination therapy has become common practice to treat patients infected with extreme drug-resistant A. baumannii. Herein we report a case of extreme drug-resistant A. baumannii infection successfully treated with tigecycline and amikacin.
Abstract
Infections due to multidrug resistant Acinetobacter baumannii have become a challenging problem in intensive care units. Tigecycline is a derivative of minocyline, and has provided new hope for the treatment of multidrug-resistant A. baumannii infections. Because isolates showing reduced susceptibility to minocycline or tigecycline have emerged in many countries, empirical combination therapy has become common practice to treat patients infected with extreme drug-resistant A. baumannii. Herein we report a case of extreme drug-resistant A. baumannii infection successfully treated with tigecycline and amikacin.
참고문헌 (20)
- Wadi JA, "Multidrug resistant acinetobacter nosocomial meningitis treated successfully with parenteral tigecycline", Ann Saudi Med, 27, pp.456~458 (2007)
- Rice LB, "Challenges in identifying new antimicrobial agents effective for treating infections with acinetobacter baumannii and pseudomonas aeruginosa", Clin Infect Dis, 43(2), pp.S100~S105 (2006)
- Moland ES, "In vitro activity of tigecycline against multidrug-resistant acinetobacter baumannii and selection of tigecycline-amikacin synergy", Antimicrob Agents Chemother, 52, pp.2940~2942 (2008)
- Abbo A, "Multidrug-resistant acinetobacter baumannii", Emerg Infect Dis, 11, pp.22~29 (2005)
- Souli M, "Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe", Euro Surveill, 13 (2008)
- Nemec A, "Emergence of carbapenem resistance in acinetobacter baumannii in the czech republic is associated with the spread of multidrug-resistant strains of European clone II", J Antimicrob Chemother, 62, pp.484~489 (2008)
- Li J, "Heteroresistance to colistin in multidrug-resistant acinetobacter baumannii", Antimicrob Agents Chemother, 50, pp.2946~2950 (2006)
- Karageorgopoulos DE, "Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) acinetobacter infections: a review of the scientific evidence", J Antimicrob Chemother, 62, pp.45~55 (2008)
- Pankey GA, "Tigecycline", J Antimicrob Chemother, 56, pp.470~480 (2005)
- Milatovic D, "Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates", Antimicrob Agents Chemother, 47, pp.400~404 (2003)
- Petersen PJ, "In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate staphylococcus aureus and other resistant gram-positive pathogens", Antimicrob Agents Chemother, 46, pp.2595~2601 (2002)
- Rhomberg PR, "In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum", Diagn Microbiol Infect Dis, 42, pp.145~147 (2002)
- Ong CT, "Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs)", J Antimicrob Chemother, 56, pp.498~501 (2005)
- Betriu C, "In vitro activity of tigecycline against Bacteroides species", J Antimicrob Chemother, 56, pp.349~352 (2005)
- Navon-Venezia S, "High tigecycline resistance in multidrug-resistant acinetobacter baumannii", J antimicrob Chemother, 59, pp.772~774 (2007)
- Insa R, "In vitro activity of tigecycline against clinical isolates of acinetobacter baumannii and stenotrophomonas maltophilia", J Antimicrob Chemother, 59, pp.583~585 (2007)
- Capone A, "In vitro activity of tigecycline against multidrug-resistant acinetobacter baumannii", J Antimicrob Chemother, 62, pp.422~423 (2008)
- Lolans K, "Multicity outbreak of carbapenem-resistant acinetobacter baumannii isolates producing the carbapenemase OXA-40", Antimicrob Agents Chemother, 50, pp.2941~2945 (2006)
- Zhang YY, "In vitro activities of tigecycline against clinical isolates from Shanghai, China", Diagn Microbiol Infect Dis, 50, pp.267~281 (2004)
- Principe L, "In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant acinetobacter baumannii", Ann Clin Microbiol Antimicrob, 8, pp.18~ (2009)